Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
The profitability profile from 2015 to 2019 reveals a significant divergence between production efficiency and overall bottom-line performance. While gross margins remained robust and elevated after 2015, operating and net margins transitioned into sustained negative territory, indicating a systemic inability to translate top-line revenue into operating or net income during the latter half of the period.
- Gross Profit Margin
- A substantial increase occurred between 2015 and 2016, rising from 68.08% to 87.23%. Following this peak, a marginal downward trend was observed through 2019, ending at 84.50%. This indicates a consistently high capacity to manage direct costs of goods sold relative to revenue.
- Operating and Net Profit Margins
- Operating margins remained negative throughout the entire period, with a notable decline to -39.57% in 2018 before a partial recovery to -27.63% in 2019. Net profit margins exhibited extreme volatility, peaking at 102.76% in 2016—suggesting the impact of significant non-operating gains—before collapsing to -25.88% in 2017 and continuing a downward trajectory to -32.76% by 2019.
- Return on Equity (ROE) and Return on Assets (ROA)
- Both ROE and ROA followed a similar trajectory of initial growth followed by persistent deterioration. ROE peaked at 19.65% in 2016 but fell sharply into negative territory starting in 2017, reaching -9.06% in 2019. Similarly, ROA rose to 11.61% in 2016 before descending to -5.57% by the end of the analyzed period, reflecting a decline in the efficiency of utilizing both shareholder equity and total assets to generate profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Gross Profit Margin
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Gross profit | 13,595,800) | 13,596,000) | 13,772,700) | 12,709,800) | 10,260,600) | |
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 84.50% | 86.12% | 86.40% | 87.23% | 68.08% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Gross profit margin = 100 × Gross profit ÷ Net revenues
= 100 × 13,595,800 ÷ 16,088,900 = 84.50%
2 Click competitor name to see calculations.
The profitability profile is characterized by a substantial increase in operational efficiency between 2015 and 2016, followed by a period of relative stability with a gradual downward trajectory in margins through 2019.
- Gross Profit Margin Evolution
- A significant expansion in the gross profit margin occurred between 2015 and 2016, rising from 68.08% to 87.23%. Following this peak, a consistent but marginal decline is observed over the subsequent three years, with the margin contracting to 84.50% by December 31, 2019.
- Net Revenue Performance
- Net revenues exhibited minor fluctuations during the analyzed period. A slight contraction occurred in 2016, followed by a recovery to 15,940.7 million in 2017. Revenues remained relatively stable thereafter, closing at 16,088.9 million in 2019.
- Gross Profit Trends
- Gross profit experienced a sharp ascent from 10,260.6 million in 2015 to a peak of 13,772.7 million in 2017. In the final two years of the period, gross profit plateaued, with values in 2018 and 2019 remaining nearly identical at approximately 13,596 million.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Profit Margin
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Operating loss | (4,445,300) | (6,247,600) | (5,921,200) | (1,825,500) | (3,014,500) | |
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | -27.63% | -39.57% | -37.15% | -12.53% | -20.00% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Operating profit margin = 100 × Operating loss ÷ Net revenues
= 100 × -4,445,300 ÷ 16,088,900 = -27.63%
2 Click competitor name to see calculations.
Analysis of the operating performance from 2015 through 2019 reveals a period of sustained operating losses despite a general upward trend in net revenues. The operational efficiency, as measured by the operating profit margin, exhibited significant volatility, reaching its lowest point in 2018 before showing a partial recovery in the final year of the period.
- Net Revenue Trends
- Revenues remained relatively stable with a gradual overall increase, moving from $15.07 billion in 2015 to $16.09 billion by 2019. A brief contraction occurred in 2016, where revenues dipped to $14.57 billion, followed by a period of steady growth through 2019.
- Operating Loss Trajectory
- Operating losses experienced substantial fluctuations over the five-year span. An initial improvement was observed in 2016, with losses narrowing to $1.83 billion. However, this was followed by a sharp escalation in losses during 2017 and 2018, reaching a peak loss of $6.25 billion. By 2019, the operating loss was reduced to $4.45 billion, suggesting a moderate recovery in cost management or operational scale.
- Operating Profit Margin Analysis
- The operating profit margin remained negative throughout the entire period, indicating that operating expenses consistently exceeded net revenues. The margin reached its most favorable point in 2016 at -12.53% but deteriorated rapidly over the next two years, hitting a minimum of -39.57% in 2018. This suggests a period of significant operational misalignment or high non-recurring expenses relative to revenue growth. A recovery trend began in 2019, as the margin improved to -27.63%.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Profit Margin
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income (loss) attributable to shareholders | (5,271,000) | (5,096,400) | (4,125,500) | 14,973,400) | 3,915,200) | |
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Profitability Ratio | ||||||
| Net profit margin1 | -32.76% | -32.28% | -25.88% | 102.76% | 25.98% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Net profit margin = 100 × Net income (loss) attributable to shareholders ÷ Net revenues
= 100 × -5,271,000 ÷ 16,088,900 = -32.76%
2 Click competitor name to see calculations.
The financial performance from 2015 to 2019 is characterized by a severe deterioration in profitability despite the maintenance of a stable revenue base. While net revenues remained relatively consistent, fluctuating between approximately $14.6 billion and $16.1 billion, net income experienced extreme volatility, transitioning from significant gains to sustained annual losses.
- Net Profit Margin Volatility
- The net profit margin exhibited an erratic trajectory, starting at 25.98% in 2015 and surging to an anomalous 102.76% in 2016. This spike indicates that net income for 2016 exceeded total revenues, suggesting the influence of substantial non-operating gains or one-time accounting adjustments. Following this peak, the margin entered a period of sharp decline, becoming negative in 2017 (-25.88%) and continuing to erode through 2019, ending at -32.76%.
- Net Income and Revenue Divergence
- A clear divergence is observed between top-line revenue and bottom-line earnings. Between 2017 and 2019, net revenues grew modestly from $15.9 billion to $16.1 billion; however, net losses expanded during the same period, moving from $4.1 billion to $5.3 billion. This pattern confirms that the decline in the net profit margin is driven by a substantial increase in expenses or losses rather than a failure to generate sales.
- Profitability Trend Summary
- The trend indicates a transition from a highly profitable state in 2015 and 2016 to a state of persistent net losses. The consistency of the negative margins from 2017 through 2019 suggests a structural shift in the cost profile or the impact of significant recurring non-cash charges that have outweighed operational revenues.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Equity (ROE)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income (loss) attributable to shareholders | (5,271,000) | (5,096,400) | (4,125,500) | 14,973,400) | 3,915,200) | |
| Shareholders’ equity | 58,173,600) | 65,114,100) | 73,821,100) | 76,192,700) | 76,591,400) | |
| Profitability Ratio | ||||||
| ROE1 | -9.06% | -7.83% | -5.59% | 19.65% | 5.11% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
ROE = 100 × Net income (loss) attributable to shareholders ÷ Shareholders’ equity
= 100 × -5,271,000 ÷ 58,173,600 = -9.06%
2 Click competitor name to see calculations.
The analysis of profitability indicators between 2015 and 2019 reveals a significant transition from positive returns to a sustained period of net losses. A sharp peak in profitability occurred in 2016, followed by a consistent deterioration in both net income and shareholders' equity through the end of the period.
- Return on Equity (ROE) Trend
- The ROE exhibited extreme volatility, rising from 5.11% in 2015 to a peak of 19.65% in 2016. This was followed by a precipitous decline into negative territory, with the ratio falling to -5.59% in 2017, -7.83% in 2018, and reaching -9.06% by December 31, 2019. This trajectory indicates a failure to generate positive returns on invested capital over the final three years of the analyzed period.
- Net Income Performance
- Net income attributable to shareholders showed a dramatic surge in 2016, reaching approximately 14.97 billion US dollars. However, the company shifted to a loss-making position starting in 2017, with annual losses expanding from 4.13 billion US dollars in 2017 to 5.27 billion US dollars in 2019.
- Shareholders' Equity Erosion
- A steady contraction in the equity base is observed over the five-year period. Shareholders' equity decreased from 76.59 billion US dollars in 2015 to 58.17 billion US dollars in 2019. The simultaneous decrease in equity and the increase in net losses have contributed to the accelerating negative ROE.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Assets (ROA)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income (loss) attributable to shareholders | (5,271,000) | (5,096,400) | (4,125,500) | 14,973,400) | 3,915,200) | |
| Total assets | 94,699,100) | 101,787,600) | 118,341,900) | 128,986,300) | 135,840,700) | |
| Profitability Ratio | ||||||
| ROA1 | -5.57% | -5.01% | -3.49% | 11.61% | 2.88% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
ROA = 100 × Net income (loss) attributable to shareholders ÷ Total assets
= 100 × -5,271,000 ÷ 94,699,100 = -5.57%
2 Click competitor name to see calculations.
The financial performance between 2015 and 2019 is characterized by significant volatility in profitability, transitioning from a period of growth to a sustained period of net losses. A sharp peak in efficiency was observed in 2016, followed by a consistent deterioration in the return on assets through 2019.
- Return on Assets (ROA) Trend
- The ROA exhibited a dramatic fluctuation, rising from 2.88% in 2015 to a peak of 11.61% in 2016. However, this growth was not sustained, as the ratio shifted to a negative 3.49% in 2017 and continued to decline further to -5.01% in 2018 and -5.57% in 2019. This downward trajectory indicates a diminishing ability to generate profits from the company's asset base.
- Net Income Correlation
- The volatility in ROA is directly tied to the performance of net income. A substantial increase in net income attributable to shareholders occurred in 2016, reaching 14.97 billion US dollars. Conversely, the company entered a period of net losses starting in 2017, with losses deepening from 4.13 billion US dollars in 2017 to 5.27 billion US dollars by 2019. The persistence of these losses is the primary driver of the negative ROA observed in the final three years of the period.
- Asset Base Contraction
- Total assets showed a steady and consistent decline over the five-year period, decreasing from 135.84 billion US dollars in 2015 to 94.70 billion US dollars in 2019. While a shrinking asset base can sometimes mathematically inflate ROA if income remains stable, the precipitous drop in net income far outweighed the reduction in total assets, resulting in the observed negative return trend.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?